£120.00
103 in stock
For research use only — Not for human or animal use
Our Retatrutide 20mg vial is a triple receptor agonist studied for its role in metabolism, appetite regulation, and body weight management. Developed by Eli Lilly, Retatrutide has become one of the most discussed compounds in obesity and metabolic research because it targets three separate hormone pathways involved in energy balance and nutrient regulation.
Unlike earlier compounds that focus on a single receptor, Retatrutide interacts with GLP-1, GIP, and glucagon receptors simultaneously. Researchers are particularly interested in how this combined mechanism may influence appetite signalling, energy expenditure, and metabolic adaptation over longer observation periods.
Its emergence has led to comparisons with compounds such as Wegovy and Mounjaro, particularly following published clinical trial data showing significant changes in body weight and metabolic markers.
Retatrutide is a synthetic peptide designed to activate three hormone receptors associated with metabolism and energy regulation:
This triple-agonist approach has made Retatrutide unique within metabolic research because it combines pathways that influence both energy intake and energy utilisation.
Researchers continue studying whether activating all three receptors together may create broader metabolic effects than single or dual receptor agonists.
Interest in Retatrutide increased significantly following the publication of Phase 2 clinical trial data in the New England Journal of Medicine.
In a 48-week study involving adults with obesity, participants receiving the highest weekly dose achieved an average body weight reduction of up to 24.2%. Researchers also observed improvements in metabolic markers, including blood glucose regulation and triglyceride levels.
One reason researchers are interested in Retatrutide is that weight reduction continued throughout much of the observation period, suggesting the metabolic response had not fully plateaued by week 48.
Current research focuses on:
Ongoing Phase 3 TRIUMPH studies continue evaluating longer observation periods and broader metabolic outcomes.
| Compound | Primary Receptors | Main Research Focus |
|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | Appetite regulation and glucose control |
| Tirzepatide (Mounjaro) | GLP-1 + GIP | Metabolic signalling and body weight management |
| Retatrutide | GLP-1 + GIP + Glucagon | Energy expenditure, appetite regulation, and metabolic adaptation |
The addition of glucagon receptor activity is one of the key reasons Retatrutide has generated significant attention within metabolic research, as researchers continue exploring whether it may influence calorie expenditure differently from earlier receptor agonists.
Research involving Retatrutide has explored several areas related to metabolism, appetite regulation, and body weight management.
Published studies have investigated:
Researchers are particularly interested in how combining GLP-1, GIP, and glucagon receptor activity may influence broader metabolic systems compared with single-pathway compounds.
This research focuses on how appetite regulation, energy use, and metabolic signalling work together within the body.
As with similar receptor agonists, side effects continue to be evaluated through clinical trials. Reported observations have included nausea, diarrhoea, vomiting, and other gastrointestinal effects, most commonly during dose-escalation periods. These events were generally reported as mild to moderate in severity.
Our Retatrutide 20mg vial is supplied as a dry peptide formulation intended for laboratory handling and analytical observation protocols.
Reconstitution should be carried out under standard laboratory conditions using validated preparation procedures suitable for assay and stability requirements.
Standard handling practices include:
Following structured laboratory protocols helps support formulation stability and analytical consistency throughout observation periods.
Disclaimer: This product is sold strictly for research purposes only. Not for human consumption.
Discount Applied Successfully!
Your savings have been added to the cart.
